Literature DB >> 7677389

Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference.

J Burke1, A Kharlamb, T Shan, E Runde, E Padillo, C Manlapaz, L Wheeler.   

Abstract

Brimonidine is a relatively selective alpha-2 adrenoceptor agonist that is being developed for the treatment of glaucoma. Because brimonidine is chemically related to clonidine and has affinity for the nonadrenergic imidazoline receptor, its ocular effects may be unrelated to alpha-2 receptor activation. The objective of this study was to determine the pharmacology of the intraocular pressure (IOP) response to brimonidine in rabbits and monkeys and the side effects (miosis, cardiovascular depression) in monkeys. Conscious albino rabbits and cynomolgus monkeys were pretreated topically with the following receptor antagonists: rauwolscine (alpha-2), idazoxan (alpha-2, imidazoline), SKF 105854 (vascular postjunctional alpha-2), and prazosin (alpha-1). Intraocular pressure, pupil size, or blood pressure/heart rate was monitored noninvasively for 6 hours following dosing. Binding experiments were performed using [3H]brimonidine in membrane preparations from rabbit iris/ciliary body and from monkey cerebral cortex and brain stem. In rabbits, the ocular hypotensive response to brimonidine was unilateral and was inhibited by rauwolscine > idazoxan >> SKF 105854 = prazosin; this ranked order of potency correlated with displacement of [3H]brimonidine in the rabbit iris/ciliary body. In monkeys, brimonidine decreased IOP bilaterally and suppressed cardiovascular function suggesting a CNS site of action. Intraocular pressure and cardiovascular responses to brimonidine were inhibited by idazoxan >> rauwolscine > SKF 105854 = prazosin; a similar profile was obtained for displacement of [3H]brimonidine in monkey brain tissue. Both rauwolscine and idazoxan inhibited the miotic response to brimonidine in monkeys. Taken together, these results indicate that brimonidine stimulates an ocular alpha-2 adrenoceptor to decrease IOP in the rabbit and a CNS imidazoline receptor to decrease IOP, blood pressure, and heart rate in the cynomolgus monkey. The miotic response in the monkey is mediated by an alpha-2 adrenoceptor. The alpha-1 and vascular postjunctional alpha-2 adrenoceptors do not appear to play a role in mediating these responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677389     DOI: 10.1111/j.1749-6632.1995.tb32392.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Effects of brimonidine ingestion on cardiovascular responses and renal function in conscious dogs.

Authors:  S Suwanwipat; C Buranakarl; N Chaiyabutr
Journal:  Vet Res Commun       Date:  2006-12-28       Impact factor: 2.459

Review 2.  Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.

Authors:  J C Adkins; J A Balfour
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

3.  Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.

Authors:  B Chiang; Y C Kim; A C Doty; H E Grossniklaus; S P Schwendeman; M R Prausnitz
Journal:  J Control Release       Date:  2016-02-28       Impact factor: 9.776

4.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

5.  Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop.

Authors:  Morgan V Fedorchak; Ian P Conner; Joel S Schuman; Anthony Cugini; Steven R Little
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

6.  28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.

Authors:  Morgan V Fedorchak; Ian P Conner; Carlos A Medina; Jeremy B Wingard; Joel S Schuman; Steven R Little
Journal:  Exp Eye Res       Date:  2014-06-28       Impact factor: 3.467

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.